Yes, Start Statin Therapy in This Diabetic Patient
For a diabetic patient aged 40-75 years with LDL 65 mg/dL who is not on a statin, you should initiate at least moderate-intensity statin therapy regardless of the current LDL level. 1
The Core Recommendation
The 2025 ADA Standards of Care are unequivocal: all people with diabetes aged 40-75 years should be on moderate-intensity statin therapy in addition to lifestyle modifications, irrespective of baseline LDL cholesterol levels 1. The LDL of 65 mg/dL does not exempt this patient from statin therapy—diabetes itself is the indication, not the LDL number.
Determining Statin Intensity
The next critical decision is whether this patient needs moderate or high-intensity therapy:
Moderate-intensity statin (30-49% LDL reduction): Appropriate if the patient has no additional ASCVD risk factors 1
- Examples: Atorvastatin 10-20 mg, Rosuvastatin 5-10 mg
High-intensity statin (≥50% LDL reduction): Required if the patient has one or more additional ASCVD risk factors, with a goal LDL <70 mg/dL 1
- Examples: Atorvastatin 40-80 mg, Rosuvastatin 20-40 mg
Additional ASCVD Risk Factors to Assess
You must evaluate for these risk-enhancing factors that would escalate therapy to high-intensity 2, 1:
- Age ≥50 years (especially 50-75 years)
- Family history of premature ASCVD
- Hypertension
- Smoking
- Chronic kidney disease
- Elevated triglycerides (≥150 mg/dL)
- Low HDL cholesterol (<40 mg/dL men, <50 mg/dL women)
- Duration of diabetes
- Metabolic syndrome
- Chronic inflammatory conditions
If any of these are present, use high-intensity statin therapy to achieve LDL <70 mg/dL 1.
Special Age Considerations
- Age 20-39 years: Statin therapy is reasonable if additional ASCVD risk factors are present 1
- Age >75 years: If already on a statin, continue it; if statin-naive, consider initiating moderate-intensity therapy after discussing benefits and risks 1
The Evidence Base
The recommendation is supported by meta-analyses of over 18,000 people with diabetes showing a 9% reduction in all-cause mortality and 13% reduction in vascular mortality for each 39 mg/dL reduction in LDL cholesterol 1. The benefit exists even when baseline LDL is already low—diabetes confers independent cardiovascular risk that statins address through mechanisms beyond simple LDL lowering.
Monitoring After Initiation
Once you start the statin 1:
- Check lipid panel at 4-12 weeks after initiation
- Reassess annually thereafter
- This monitoring improves adherence and allows dose titration if needed
Common Pitfall to Avoid
Do not withhold statins because the LDL is "already low." The 2018 ACC/AHA guidelines specify that statin therapy should be started in diabetic patients with LDL ≥70 mg/dL 2, and the 2025 ADA guidelines make clear that moderate-intensity therapy is recommended for all diabetic patients 40-75 years regardless of baseline LDL 1. The patient's LDL of 65 mg/dL is close to this threshold, and diabetes itself—not just the LDL number—drives the indication.